<i>In Vitro</i> Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
Dee Shortridge, Jennifer M Streit, Rodrigo E. Mendes, Mariana Castanheira
Abstract
Cefiderocol is the first siderophore-conjugated cephalosporin approved for use in the treatment of human bacterial infections. Cefiderocol has broad-spectrum Gram-negative activity against difficult-to-treat bacterial pathogens that can cause serious infections.
Topics & Concepts
CephalosporinAntimicrobialSiderophoreBiologyMicrobiologyAntibioticsBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyInfections and bacterial resistance